Lobbying

Sumitomo Pharma's latest lobbying report covers Q1 2024, at $50K. Its first report covers Q4 2022; the issues it reports most are Health Issues and Medicare/Medicaid.

Sumitomo Pharma

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Sumitomo Pharma lobbying by quarter
Sumitomo Pharma lobbying by quarter
QuarterAmountReports
Q4 2022$50K1
Q1 2023$50K1
Q2 2023$50K1
Q3 2023$50K1
Q4 2023$50K1
Q1 2024$50K1
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$150K · 6 reports
  • Medicare and Medicaid$150K · 6 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES6 reports
  • SENATE6 reports

Firms it paid

Firm
Jeffrey J. Kimbell & Associates$300K6 quarters

Former officials lobbying for it

Former position
JOHN HERZOGHealth Aide, Sen. Lamar Alexander; Special Assistant to the Assistant to the President for Legislative Affairs, Executive Office of the PresidentQ1 2024
JOHN R RAYLegislative Assistant, Rep. Mike KellyQ1 2024
KEITH STUDDARDLegislative Director, Rep. Marsha BlackburnQ1 2024
KELSEY CARLSONSpecial Assistant, National Security Council; Special Assistant, International Trade Administration, Dept of Commerce; Policy Advisor, Office of the Deputy Chief of Staff, Executive Office of the President; Confidential Assistant, Dept of CommerceQ1 2024

Lobbying reports

Filed by
24/04/19for Q1 2024Jeffrey J. Kimbell & Associates$50K
24/01/19for Q4 2023Jeffrey J. Kimbell & Associates$50K
23/10/20for Q3 2023Jeffrey J. Kimbell & Associates$50K
23/07/19for Q2 2023Jeffrey J. Kimbell & Associates$50K
23/04/24for Q1 2023Jeffrey J. Kimbell & Associates$50K
23/01/18for Q4 2022Jeffrey J. Kimbell & Associates$50K